FOXC1 Is a Potential Prognostic Biomarker with Functional Significance in Basal-like Breast Cancer

PS Ray, JH Wang, Y Qu, MS Sim, J Shamonki, SP Bagaria, X Ye, BY Liu, D Elashoff, DS Hoon, MA Walter, John Martens, AL Richardson, AE Giuliano, XJ Cui

Research output: Contribution to journalArticleAcademicpeer-review


Gene expression signatures for a basal-like breast cancer (BLBC) subtype have been associated with poor clinical outcomes, but a molecular basis for this disease remains unclear. Here, we report overexpression of the transcription factor FOXC1 as a consistent feature of BLBC compared with other molecular subtypes of breast cancer. Elevated FOXC1 expression predicted poor overall survival in BLBC (P = 0.0001), independently of other clinicopathologic prognostic factors including lymph node status, along with a higher incidence of brain metastasis (P = 0.02) and a shorter brain metastasis-free survival in lymph node-negative patients (P < 0.0001). Ectopic overexpression of FOXC1 in breast cancer cells increased cell proliferation, migration, and invasion, whereas shRNA-mediated FOXC1 knockdown yielded opposite effects. Our findings identify FOXC1 as a theranostic biomarker that is specific for BLBC, offering not only a potential prognostic candidate but also a potential molecular therapeutic target in this breast cancer subtype. Cancer Res; 70(10); 3870-6. (C) 2010 AACR.
Original languageUndefined/Unknown
Pages (from-to)3870-3876
Number of pages7
JournalCancer Research
Issue number10
Publication statusPublished - 2010

Cite this